Tags

Type your tag names separated by a space and hit enter

Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
Blood Coagul Fibrinolysis. 2012 Jun; 23(4):331-4.BC

Abstract

This case report describes a patient with relapsed primary immune thrombocytopenic purpura (ITP), in which splenectomy was not possible due to the persistence of a low platelet count despite treatment with corticosteroids, intravenous immunoglobulins (IVIG) and platelet transfusion treatment. As an attempt to increase platelet count prior to performing splenectomy, the thrombopoietin receptor agonist, romiplostim, was administered in combination with steroids and IVIG. A single administration of romiplostim was found to be markedly effective, allowing a rapid and notable platelet increase, required for a well tolerated splenectomy. This case confirms the potent activity of romiplostim in ITP, and indicates that patients with recurrent primary ITP who are unresponsive to conventional immunosuppressive therapy may benefit from the addition of a short course of romiplostim.

Authors+Show Affiliations

S.C.D.U. Ematologia e Terapie Cellulari, A.O. Ord. Mauriziano-Umberto I, Torino, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

22343685

Citation

Sivera, Piera, et al. "Use of the Novel Thrombopoietin Receptor-agonist Romiplostim, in Combination With Steroids and Immunoglobulins for the Increase of Platelets Prior to Splenectomy, in Refractory Immune Thrombocytopenia: a Case Report." Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, vol. 23, no. 4, 2012, pp. 331-4.
Sivera P, Ruella M, Gueli A, et al. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagul Fibrinolysis. 2012;23(4):331-4.
Sivera, P., Ruella, M., Gueli, A., Hu, H., Wade, M., & Tarella, C. (2012). Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, 23(4), 331-4. https://doi.org/10.1097/MBC.0b013e3283513a97
Sivera P, et al. Use of the Novel Thrombopoietin Receptor-agonist Romiplostim, in Combination With Steroids and Immunoglobulins for the Increase of Platelets Prior to Splenectomy, in Refractory Immune Thrombocytopenia: a Case Report. Blood Coagul Fibrinolysis. 2012;23(4):331-4. PubMed PMID: 22343685.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. AU - Sivera,Piera, AU - Ruella,Marco, AU - Gueli,Angela, AU - Hu,Huijing, AU - Wade,Muhamed, AU - Tarella,Corrado, PY - 2012/2/21/entrez PY - 2012/2/22/pubmed PY - 2012/8/28/medline SP - 331 EP - 4 JF - Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis JO - Blood Coagul Fibrinolysis VL - 23 IS - 4 N2 - This case report describes a patient with relapsed primary immune thrombocytopenic purpura (ITP), in which splenectomy was not possible due to the persistence of a low platelet count despite treatment with corticosteroids, intravenous immunoglobulins (IVIG) and platelet transfusion treatment. As an attempt to increase platelet count prior to performing splenectomy, the thrombopoietin receptor agonist, romiplostim, was administered in combination with steroids and IVIG. A single administration of romiplostim was found to be markedly effective, allowing a rapid and notable platelet increase, required for a well tolerated splenectomy. This case confirms the potent activity of romiplostim in ITP, and indicates that patients with recurrent primary ITP who are unresponsive to conventional immunosuppressive therapy may benefit from the addition of a short course of romiplostim. SN - 1473-5733 UR - https://www.unboundmedicine.com/medline/citation/22343685/Use_of_the_novel_thrombopoietin_receptor_agonist_romiplostim_in_combination_with_steroids_and_immunoglobulins_for_the_increase_of_platelets_prior_to_splenectomy_in_refractory_immune_thrombocytopenia:_a_case_report_ L2 - https://doi.org/10.1097/MBC.0b013e3283513a97 DB - PRIME DP - Unbound Medicine ER -